Skip to main content

Table 1 Targeted agents in development for HCC

From: Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview

Agent Anti-angiogenic targets Anti-proliferative targets Clinical Development
  VEGF VEGFR PDGFR EGFR Raf mTOR  
Bevacizumab       Phase II ongoing
Brivanib       Phase II recruiting
Cediranib       Phase II recruiting
Erlotinib       Phase II complete
Gefitinib       Phase II complete
Cetuximab       Phase II complete
Lapatinib       Phase II ongoing
RAD001       Phase I/II recruiting
Sorafenib*     Phase III complete
Sunitinib*      Phase II ongoing
Thalidomide       Phase III recruiting
  1. *Sorafenib and sunitinib are multi-tyrosine kinase inhibitors having both anti-proliferative and anti-angiogenic effects